UFO
Recent MRNS News
- The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:01:43 AM
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus • Business Wire • 06/17/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/06/2024 08:55:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 10:35:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 11:05:13 AM
- Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program • Business Wire • 05/17/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:07:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:18 AM
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 11:00:00 AM
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference • Business Wire • 05/02/2024 12:00:00 PM
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 • Business Wire • 05/01/2024 12:00:00 PM
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results • Business Wire • 04/15/2024 11:00:00 AM
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • Business Wire • 04/05/2024 08:00:00 PM
- Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review • Business Wire • 03/27/2024 12:41:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:14:45 PM
- Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:05:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:06:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:05:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:05:24 PM
- Marinus Pharmaceuticals to Present at Upcoming Investor Conferences • Business Wire • 02/21/2024 12:00:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM